Oral presentation during the session Tolerance Delivery Systems & Trial Design Optimization showcases the value the Company’s novel approach to specifically target immune cells involved in autoimmune diseases
Imcyse’s insulin-based IMOTOPETM has shown promising results in a Phase Ib study in patients with Type-1 diabetes
With an initial focus on autoimmune diseases, Imcyse’s platform has the potential to address a wide range of indications in the vast field of immunology.
Liège, Belgium, February 24, 2020 – Imcyse a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe chronic autoimmune diseases, today announced that the Company will present a late-breaking abstract on its ImotopeTM-based antigen specific immunotherapies for autoimmune diseases at the 3rd Antigen-Specific Immune Tolerance summit 2020 (ASIT), taking place in Boston, MA, February 25 – 27. ASIT is considered the thought-leading platform dedicated to overcoming key challenges currently impeding drug development for tolerance inducing therapeutics.